4//SEC Filing
CORMORANT PRIVATE HEALTHCARE FUND I, LP 4
Accession 0001567619-20-018747
CIK 0001593899other
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 4:01 PM ET
Size
26.0 KB
Accession
0001567619-20-018747
Insider Transaction Report
Form 4
Transactions
- Conversion
Series D Convertible Preferred Stock
2020-11-03−712,250→ 0 total(indirect: See Footnotes)→ Common Stock (712,250 underlying) - Conversion
Common Stock
2020-11-03+6,411,355→ 6,411,355 total(indirect: See Footnotes) - Conversion
Series A Convertible Preferred Stock
2020-11-03−1,000,000→ 0 total(indirect: See Footnotes)→ Common Stock (1,000,000 underlying) - Conversion
Series B Convertible Preferred Stock
2020-11-03−1,650,165→ 0 total(indirect: See Footnotes)→ Common Stock (1,650,165 underlying) - Conversion
Series C Convertible Preferred Stock
2020-11-03−2,631,580→ 0 total(indirect: See Footnotes)→ Common Stock (2,631,580 underlying) - Conversion
Series D-1 Convertible Preferred Stock
2020-11-03−417,360→ 0 total(indirect: See Footnotes)→ Common Stock (417,360 underlying)
Footnotes (8)
- [F1]Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.
- [F2]Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
- [F3]Represents (i) 2,043,170 shares of Common Stock held by the Master Fund, (ii) 3,106,168 shares of Common Stock held by Fund I, (iii) 912,612 shares of Common Stock held by Fund II, and (iv) 349,405 shares of Common Stock held by the Account.
- [F4]The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 842,500 shares held by the Master Fund and (ii) 157,500 shares held by the Account.
- [F5]The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 396,040 shares held by the Master Fund, (ii) 1,155,115 shares held by Fund I, and (iii) 99,010 shares held by the Account.
- [F6]The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 587,632 shares held by the Master Fund, (ii) 1,951,053 shares held by Fund I, and (iii) 92,895 shares held by the Account.
- [F7]The Series D Convertible Preferred Stock represented, on an as-converted basis, (i) 136,823 shares held by the Master Fund and (ii) 575,427 shares held by Fund II.
- [F8]The Series D-1 Convertible Preferred Stock represented, on an as-converted basis, (i) 80,175 shares held by the Master Fund and (ii) 337,185 shares held by Fund II.
Documents
Issuer
Atea Pharmaceuticals, Inc.
CIK 0001593899
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001663781
Filing Metadata
- Form type
- 4
- Filed
- Nov 4, 7:00 PM ET
- Accepted
- Nov 5, 4:01 PM ET
- Size
- 26.0 KB